Aims: To compare the efficacy of psoriasis treatments through a systematic literature review and meta-analysis. Methods: Randomized controlled trials evaluating the Psoriasis Area and Severity Index (PASI) were identified and assessed for quality. PASI responses were modeled using a mixed-treatment comparison, which enabled the estimation of the relative effectiveness of several treatments. Sensitivity analyses were performed. Results: Twenty-two trials were included. Tumor necrosis factor (TNF) inhibitors were most likely to achieve PASI 75, with a mean relative risk (RR) of 15.57 (95% CI 12.46–19.25) versus mean RRs of 9.24 (95% CI 5.33–13.91) for systemic and 5.65 (95% CI 3.74–7.97) for T-cell therapies. Infliximab (81%) and adalimumab (71%) had greater probabilities of achieving PASI 75 than etanercept (50%). Dosage was an important determinant of outcome. Conclusions: TNF inhibitors were more effective than T cell agents; adalimumab and infliximab were more effective than systemic therapies and etanercept. Evidence-based comparisons support patient and physician decisions.

Keywords:
Biologics, Meta-analysis, Psoriasis, Randomized controlled trial, Systematic review
1.
Heydendael VM, Spuls PI, Opmeer BC, et al: Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003;349:658–665.
2.
National Psoriasis Foundation: About psoriasis: statistics. www.psoriasis.org/about/stats (accessed February 9, 2006).
3.
Lowe NJ, Prystowsky JH, Bourget T, et al: Acitretin plus UVB therapy for psoriasis: comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 1991;24:591–594.
4.
Leon A, Nguyen A, Letsinger J, Koo J: An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options. Expert Opin Pharmacother 2007;8:617–632.
5.
Youn JI, Kim BK, Suh DH: The effectiveness of modified Ingram therapy compared with severity of psoriasis. J Dermatol 1998;25:112–117.
6.
Stein KR, Pearce DJ, Feldman SR: The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg 2005;24:52–57.
7.
Koo J, Khera P: Update on the mechanisms and efficacy of biological therapies for psoriasis. J Dermatol Sci 2005;38:75–87.
8.
Weinberg JM: An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther 2003;25:2487–2505.
9.
Fredriksson T, Pettersson U: Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978;157:238–244.
10.
Jadad AR, Moore RA, Carroll D, et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12.
11.
Woolacott N, Hawkins N, Mason A, et al: Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006;10:1–233.
12.
Lu G, Ades AE: Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105–3124.
13.
Altman DG: Confidence intervals for the number needed to treat. BMJ 1998;317:1309–1312.
14.
Moher D, Cook DJ, Eastwood S, et al: Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Onkologie 2000;23:597–602.
15.
Papp KA, Tyring S, Lahfa M, et al: A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304–1312.
16.
Gottlieb AB, Matheson RT, Lowe N, et al: A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627–1632.
17.
Leonardi CL, Powers JL, Matheson RT, et al: Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014–2022.
18.
Tyring S, Gottlieb A, Papp K, et al: Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367:29–35.
19.
Gottlieb AB, Evans R, Li S, et al: Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534–542.
20.
Reich K, Nestle FO, Papp K, et al: Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367–1374.
21.
Chaudhari U, Romano P, Mulcahy LD, et al: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842–1847.
22.
Menter A, Feldman SR, Weinstein GD, et al: A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007;56:31.e1–31.e15.
23.
Gordon KB, Langley RG, Leonardi C, et al: Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006;55:598–606.
24.
Saurat J, Stingl G, Dubertret L, et al; CHAMPION Study Investigators: Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol2008;158:558–566.
25.
Menter A, Tyring SK, Gordon K, et al: Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008;58:105–115.
26.
Gordon KB, Papp KA, Hamilton TK, et al: Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003;290:3073–3080.
27.
Dubertret L, Sterry W, Bos JD, et al: Clinical experience acquired with the efalizumab (Raptiva®) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 2006;155:170–181.
28.
Papp KA, Bressinck R, Fretzin S, et al: Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol 2006;45:605–614.
29.
Leonardi CL, Papp KA, Gordon KB, et al: Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005;52:425–433.
30.
Lebwohl M, Tyring SK, Hamilton TK, et al: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004–2013.
31.
Ortonne JP: Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2003;17:12–16.
32.
Krueger GG: Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plague psoriasis. J Eur Acad Dermatol Venereol 2003;17:17–24.
33.
Ellis CN, Krueger GG; Alefacept Clinical Study Group: Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248–255.
34.
Schlessinger J, Pariser R, Park S, Wierz G: Evaluation of the efficacy and safety of alefacept in patients for whom conventional psoriasis therapies are ineffective or inappropriate (abstract P2771). J Am Acad Dermatol 2007;56:abstract 192.
35.
Meffert H, Brautigam M, Farber L, Weidinger G: Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile. Acta Derm Venereol 1997;77:137–141.
36.
Smith CH, Anstey AV, Barker JN, et al: British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005;153:486–497.
37.
Sterry W, Barker J, Boehncke WH, et al: Biological therapies in the systemic management of psoriasis: international consensus conference. Br J Dermatol 2004;151:3–17.
38.
Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE: Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999;141:185–191.
39.
Pearce DJ, Higgins KB, Stealey KH, et al: Adverse events from systemic therapies for psoriasis are common in clinical practice. J Dermatolog Treat 2006;17:288–293.
40.
Gordon KB, Langley RG, Leonardi C, et al: Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006;55:598–606.
41.
Nixon RM, Bansback N, Brennan A: Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Stat Med 2007;26:1237–1254.
42.
Brimhall A, King L, Licciardone J, Jacobe H, Menter A: Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 2008;159:274–285.
43.
Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W: Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008;159:513–526.
44.
Sutton A, Ades AE, Cooper N, Abrams K: Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 2008;26:753–767.
45.
National Institute for Health and Clinical Excellence: Guide to the methods of technology appraisal. London, NICE, 2008. www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf (accessed December 11, 2008).
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.